Towards a transcriptomic biomarker for the classification of melanocytic neoplasms
PLOS Genetics · 2025
DOI: 10.1371/journal.pgen.1011869 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, 2025. Verfasst von Elizabeth S Borden und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, United States of America. Hauptthemen laut MEDLINE: Melanoma, Biomarkers, Tumor, Transcriptome, Skin Neoplasms. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NCI NIH HHS, BLRD VA, National Institutes of Health.
Abstract (Originalsprache)
Histopathologic diagnosis of thin, invasive cutaneous melanoma (CM) is only 34–62% accurate. Therefore, we sought to develop a transcriptomic biomarker to distinguish benign from malignant melanocytic neoplasms. We generated a targeted RNA-Sequencing dataset (TempO-Seq) of benign nevi (BN; n = 50) and CM (Breslow depth ≤ 1.0 mm; n = 51) and demonstrated enrichment of immune-related pathways among the 450 differentially expressed genes. Next, we trained a putative transcriptomic biomarker in two datasets, including BN and CM, and one dataset with CM in association with a nevus, macrodissected into CM and nevus regions. We refer to the nevus portion of CM in association with a nevus as progressing nevi (PN), since these nevi progressed to CM. Principal component analysis showed that PN samples clustered in a component intermediate to BN and CM. Ordinal regularized regression selected PYGL, AP000845.1, PHYHIP, WSCD1, FBXO7, TRPM1, SLC4A4, NALCN, FRMD4B, HHATL, COL1A1, CRYM, EPOP, RGS1, KRT6C, IGHG1, CNTN1, MMP11, GZMM, AP001880.1, TTYH3, TMEM132A, and PRAME ; these genes were consistently selected in 1000 models using data from bootstrap resamples and had a single model predictive accuracy of at least 0.90 (area under the receiver operator characteristics curve). Linear regression models fit with these 23 genes in the TempO-Seq data, and publicly available microarray datasets from BN, dysplastic nevi, and CM, showed high consistency in the magnitude and directionality of gene expression differences between nevi and CM. Furthermore, immunohistochemical staining showed consistent protein-level changes in MMP11 and PYGL. These results illuminate the potential for a transcriptomic biomarker to differentiate benign from malignant melanocytic neoplasms and improve the accuracy of melanoma diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, United States of America.
- Phoenix Veterans Affairs Health Care System, Phoenix, Arizona, United States of America.
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, United States of America.
- Department of Medicine, University of Arizona College of Medicine Tucson, Tucson, Arizona, United States of America.
- Sagis Diagnostics, Houston, Texas, United States of America.
- Department of Pathology and Laboratory Medicine, Phoenix Children's Hospital, Phoenix, Arizona, United States of America.
ORCID-Profile: Elizabeth S Borden, Edgar Tapia, Danielle Vargas de Stefano, Kenneth H Buetow, Melissa A Wilson, Clara Curiel-Lewandrowski, Karen Taraszka Hastings
Förderung
- NCI NIH HHS
- BLRD VA
- National Institutes of Health
- U.S. Department of Veterans Affairs, Biomedical Laboratory Research and Development Service
- National Human Genome Research Institute
Zitieren
APA
Borden, E. S., Hastings, C. T., Prakash, N., Kuo, T., Tapia, E., Yozwiak, M., Sagerman, P., Vargas de Stefano, D., Buetow, K. H., Wilson, M. A., Curiel-Lewandrowski, C., Chow, H. S., LaFleur, B. J., & Hastings, K. T. (2025). Towards a transcriptomic biomarker for the classification of melanocytic neoplasms. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011869
Vancouver
Borden ES, Hastings CT, Prakash N, Kuo T, Tapia E, Yozwiak M, et al. Towards a transcriptomic biomarker for the classification of melanocytic neoplasms. PLOS Genetics. 2025. doi:10.1371/journal.pgen.1011869
BibTeX
@article{Borden2025,
author = {Borden, Elizabeth S and Hastings, Colin T and Prakash, Nithish and Kuo, Tyler and Tapia, Edgar and Yozwiak, Michael and Sagerman, Paul and Vargas de Stefano, Danielle and Buetow, Kenneth H and Wilson, Melissa A and Curiel-Lewandrowski, Clara and Chow, Hsiao-Hui Sherry and LaFleur, Bonnie J and Hastings, Karen Taraszka},
title = {Towards a transcriptomic biomarker for the classification of melanocytic neoplasms},
journal = {PLOS Genetics},
year = {2025},
doi = {10.1371/journal.pgen.1011869}
}
EUVIMED